Top ten innovators in pharma: Jerry Karabelas

Hannah Blake

pharmaphorum

(Continued from “Top ten innovators in pharma: Lynn Crowe”)

We asked you to nominate those who you considered to be a top innovator in pharma. We were delighted with your responses and have whittled it down to the top ten pharma innovators for this series.

This week’s top pharma innovator is Jerry Karabelas, who has over 21 years of experience working within the pharmaceutical industry, holding top positions in big pharma companies such as Novartis and GlaxoSmithKline.

Name: Argeris N. “Jerry” Karabelas

Position: Partner at Care Capital

Reasons for nomination as a pharma innovator include:

• Inspirational leader.

• While he may no longer be in pharma, he still supports innovation.

• His extensive experience in the development and marketing of pharmaceutical products is outstanding.

• A strategic and operational leader of research and development.

&nbsp,

 “His extensive experience in the development and marketing of pharmaceutical products is outstanding.”

Background:

Jerry is currently a partner at life sciences venture capital firm, Care Capital, and is also Chairman of the Board for several of Care Capital’s portfolio companies, including Human Genome Sciences and NitroMed Pharmaceuticals, as well as serving as Director for Minster Pharmaceuticals. He was also once Chairman of the Board at Vanda Pharmaceuticals and Inotek Pharmaceuticals.

Prior to Care Capital, Jerry was the founder and Chairman of the Novartis BioVenture Fund. Between 1998 and 2000, Jerry was Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, with full responsibility for Novartis Pharma, Ciba Vision and Generics. One of his main responsibilities in this role was strategic and operational leadership of research and development, which had a budget in excess of US $2 billion.

Before Novartis, Jerry was Executive Vice President of SmithKline Beeckham and looked after US and European operations, regulatory and strategic marketing. He has also been responsible for many pharmaceutical product approvals and new product launches.

Jerry holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy.

Jerry was unavailable to answer any questions.

View the next part of this series here.

European-CME-Forum-15-16-November-2012

About the nominee:

Dr Argeris “Jerry” Karabelas is a partner at Care Capital, a life sciences venture capital firm and also currently serves as Chairman of the Board for several of Care Capital’s portfolio companies, including NitroMed Pharmaceuticals and Inotek Pharmaceuticals.

Who would you nominate as a top innovator within pharma?